Responsible Institution: China Association for Science and Technology
Sponsored by: The Chinese Pharmacological Society
Editor-in-Chief: HUANG Zhili
ISSN 1009-2501
CN 34-1206/R
1Institute of Clinical Phamacology, Central South University, Changsha 410078, Hunan, China; 2Huaihua Medical Courses In General, Huaihua 418000, Hunan, China
OUYANG Dong-sheng, WU Wei-hua, TANG Zhi-rong, CHEN Rao, ZHOU Gan, HU Dong-li. Study on clinical pharmacokinetics of tegaserod hydrogen maleate tablet in healthy Chinese volunteers by LC-MS[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1419-1423.
[1] 张乐之,魏斌,周红,马来酸替加色罗[J].中国新药杂志,2002;11:968-969. [2] Vickers AE, Zollinger M, Dannecker R. et al. In vitro me-tabolism of tegaserod in human liver and intestine: assessment ofdrug interactions[J]. Drug Metab Disp, 2001;29: 1269-1276. [3] Appel S, Kumle A, Hubert M, et al. First pharmacokinetic-pharmacodynamric study in humanswith a selective 5-hydroxytryptarmine 4 receptor agonist[J]. J Clin Pharmacol,1997;37:229-237. [4] 文爱东,毕琳琳,贾艳艳,等.马来酸替加色罗分散片的人体生物等效性研究[J].中国药房,2007;18:592-594. [5] 司继刚, 王本杰,郭瑞臣.马来酸替加色罗片健康人体药代动力学试验[J].齐鲁药事,2006;25:365-367. [6] 司继刚,郭瑞臣,王本杰.马来酸替加色罗胶囊与其片剂的人体生物等效性[J].中国临床药学杂志,2006; 15:96-99. [7] Appel-Dingemanse S. Clinical phamacokinetics of tegaserod, aserotorin 5-HT(4) receplor purtial agonist with pronotile activity[J]. Clin Phamacokinet, 2002;41: 1021-1042.